RESUMO
INTRODUCTION: Severe familial hypercholesterolaemia (FH) causes premature disability and death due to atherosclerotic cardiovascular disease and is refractory to standard lipid-lowering therapies. Lipoprotein apheresis (LA) has long been a standard of care for patients with severe FH, but is invasive, expensive and time-consuming for patients and their caregivers. Newer drug therapies, including the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, may reduce the need for LA. MATERIALS AND METHODS: We audited the records of 16 patients (eight homozygous, eight heterozygous) treated with LA in Australia and New Zealand, 14 of whom subsequently commenced PCSK9 inhibitor therapy. LA was performed by cascade filtration in all centres. RESULTS: LDL-cholesterol was acutely lowered by 69 ± 7% in patients with homozygous FH and by 72 ± 9% in those with heterozygous FH, representing time-averaged reductions of 36 ± 12% and 34 ± 5%, respectively. LA was well-tolerated, and patients reported comparable quality of life to population and disease-related norms. After commencement of PCSK9 inhibitors, four of seven patients with homozygous FH had meaningful biochemical responses, with a reduction in the frequency of LA permitted in one patient and complete cessation in another. Four of seven patients with heterozygous FH were able to be managed without LA after commencing PCSK9 inhibitors. CONCLUSION: While PCSK9 inhibitors have reduced the need for LA, some patients with severe FH continue to require LA, and will require it for the foreseeable future. However, emerging therapies, including angiopoetin-like 3 inhibitors, may further reduce the need for LA.
Assuntos
Remoção de Componentes Sanguíneos/métodos , LDL-Colesterol/sangue , Hiperlipoproteinemia Tipo II/terapia , Inibidores de PCSK9 , Adolescente , Adulto , Remoção de Componentes Sanguíneos/efeitos adversos , Remoção de Componentes Sanguíneos/economia , Terapia Combinada , Feminino , Custos de Cuidados de Saúde , Humanos , Hiperlipoproteinemia Tipo II/sangue , Hiperlipoproteinemia Tipo II/psicologia , Masculino , Qualidade de Vida , Adulto JovemRESUMO
Many apheresis techniques can be performed in a blood-bank facility or a hemodialysis (HD) facility. However, it makes sense to perform apheresis in a hemodialysis facility as apheresis involves extra-corporeal circuits and because HD can be performed at the same time as apheresis (tandem procedure). Apheresis techniques comprise therapeutic plasma exchange, double-filtration plasmapheresis, and its derivative (rheopheresis and LDL-apheresis), and immunoadsorption (specific and semi-specific). We have setup an apheresis platform in our hospital that fulfills health recommendations. This process has involved financial investment and significant human resources, and has enabled us to network with different specialties (neurology, hematology, vascular medicine). We have setup protocols according to the type of pathology to be treated by apheresis, and to monitor clinical and biological data for each apheresis session. The main side effects of apheresis are a fall in blood pressure when a session is initiated, an increase in fluid overload, hypocalcemia, and the loss of some essential plasmatic factors. However, these side-effects are easily identified and can be properly managed in real time. Within two-years, we have performed 1845 apheresis sessions (134 patients). Of these, 66 received apheresis before and/or after kidney transplantation for ABO and/or HLA incompatibility (desensitization), for humoral rejection, or in the setting of relapsing focal-segmental glomerulosclerosis. Our patients' outcomes have been similar to those reported in the literature. The other 68 patients had various conditions. Because our program is now well-established, we are currently forming a specialist center to train physicians and nurses in the various apheresis techniques/procedures.
Assuntos
Remoção de Componentes Sanguíneos , Unidades Hospitalares de Hemodiálise/organização & administração , Remoção de Componentes Sanguíneos/efeitos adversos , Remoção de Componentes Sanguíneos/instrumentação , Remoção de Componentes Sanguíneos/métodos , Remoção de Componentes Sanguíneos/estatística & dados numéricos , Ácido Cítrico/administração & dosagem , Ácido Cítrico/efeitos adversos , Grupos Diagnósticos Relacionados , Glucose/administração & dosagem , Glucose/efeitos adversos , Glucose/análogos & derivados , Necessidades e Demandas de Serviços de Saúde , Hospitais Universitários/organização & administração , Humanos , Hipocalcemia/etiologia , Hipotensão/etiologia , Transplante de Rim , Equipe de Assistência ao Paciente , Utilização de Procedimentos e Técnicas , Diálise Renal , Estudos RetrospectivosRESUMO
PURPOSE OF REVIEW: Lipoprotein apheresis is a very efficient but time-consuming and expensive method of lowering levels of low-density lipoprotein cholesterol, lipoprotein(a)) and other apoB containing lipoproteins, including triglyceride-rich lipoproteins. First introduced almost 45 years ago, it has long been a therapy of "last resort" for dyslipidaemias that cannot otherwise be managed. In recent years new, very potent lipid-lowering drugs have been developed and the purpose of this review is to define the role of lipoprotein apheresis in the current setting. RECENT FINDINGS: Lipoprotein apheresis still plays an important role in managing patients with homozygous FH and some patients with other forms of hypercholesterolaemia and cardiovascular disease. In particular, patients not achieving treatment goals despite modern lipid-lowering drugs, either because these are not tolerated or the response is insufficient. Recently, lipoprotein(a) has emerged as an important cardiovascular risk factor and lipoprotein apheresis has been used to decrease lipoprotein(a) concentrations in patients with marked elevations and cardiovascular disease. However, there is considerable heterogeneity concerning the recommendations by scientific bodies as to which patient groups should be treated with lipoprotein apheresis. Lipoprotein apheresis remains an important tool for the management of patients with severe drug-resistant dyslipidaemias, especially those with homozygous FH.
Assuntos
Remoção de Componentes Sanguíneos/métodos , LDL-Colesterol/sangue , Hipercolesterolemia/terapia , Hiperlipoproteinemia Tipo II/terapia , Lipoproteína(a)/sangue , Lipoproteínas/sangue , Triglicerídeos/sangue , Remoção de Componentes Sanguíneos/efeitos adversos , Remoção de Componentes Sanguíneos/economia , Homozigoto , Humanos , Hiperlipoproteinemia Tipo II/genética , Hipolipemiantes/farmacologia , Hipolipemiantes/uso terapêutico , Inibidores de PCSK9RESUMO
BACKGROUND: US FDA draft guidance includes pathogen reduction (PR) or secondary rapid bacterial testing (RT) in its recommendations for mitigating risk of platelet component (PC) bacterial contamination. An interactive budget impact model was created for hospitals to use when considering these technologies. METHODS: A Microsoft Excel model was built and populated with base-case costs and probabilities identified through literature search and a survey of US hospital transfusion service directors. Annual costs of PC acquisition, testing, wastage, dispensing/transfusion, sepsis, shelf life, and reimbursement for a mid-sized hospital that purchases all of its PCs were compared for four scenarios: 100% conventional PCs (C-PC), 100% RT-PC, 100% PR-PC, and 50% RT-PC/50% PR-PC. RESULTS: Annual total costs were US$3.64, US$3.67, and US$3.96 million when all platelets were C-PC, RT-PC, or PR-PC, respectively, or US$3.81 million in the 50% RT-PC/50% PR-PC scenario. The annual net cost of PR-PC, obtained by subtracting annual reimbursements from annual total costs, is 6.18% above that of RT-PC. Maximum usable shelf lives for C-PC, RT-PC, and PR-PC are 3.0, 5.0, and 3.6 days, respectively; hospitals obtain PR-PC components earliest at 1.37 days. CONCLUSION: The model predicts minimal cost increase for PR-PC versus RT-PC, including cost offsets such as elimination of bacterial detection and irradiation, and reimbursement. Additional safety provided by PR, including risk mitigation of transfusion-transmission of a broad spectrum of viruses, parasites, and emerging pathogens, may justify this increase. Effective PC shelf life may increase with RT, but platelets can be available sooner with PR due to elimination of bacterial detection, depending on blood center logistics.
Assuntos
Plaquetas/microbiologia , Coleta de Amostras Sanguíneas/economia , Custos Hospitalares/estatística & dados numéricos , Transfusão de Plaquetas/economia , Infecções Bacterianas/diagnóstico , Infecções Bacterianas/economia , Infecções Bacterianas/prevenção & controle , Infecções Bacterianas/transmissão , Remoção de Componentes Sanguíneos/efeitos adversos , Remoção de Componentes Sanguíneos/economia , Remoção de Componentes Sanguíneos/estatística & dados numéricos , Coleta de Amostras Sanguíneas/métodos , Orçamentos , Humanos , Modelos Econométricos , Transfusão de Plaquetas/efeitos adversos , Transfusão de Plaquetas/estatística & dados numéricos , Estados UnidosRESUMO
BACKGROUND: Dysphagia screening is oftentimes a focus of hospitalized patients, but dysphagia can also occur in outpatient settings. Dysphagia can be overlooked by nurses and clinicians, and it is therefore important to educate nurses on the importance of dysphagia screenings. METHODS: This was a randomized prospective pilot study to compare the effect of experiential learning versus traditional PowerPoint learning regarding nurses' attitudes towards performing dysphagia screening in an outpatient setting. Twelve pre and post-test surveys were collected from nurses working in outpatient apheresis about their attitudes towards dysphagia screening. Additionally, 128 electronic medical records (EMR) were reviewed to determine if education increased the occurrence of dysphagia screening. RESULTS: There was a statistically significant difference in the pre vs. post-test group scores (P < .001), but due to small sample size, there was insufficient evidence to reject the null hypothesis that nurses had changed their attitudes towards dysphagia screening. Comparing documentation of dysphagia assessment in the EMR, there was not a significant difference in practice before or after the educational intervention (P = 0.18). CONCLUSIONS: The study results showed that the both types of teaching strategies are possible with nurses and they were receptive to both. Although the results of this study did not show a significant difference in practice, more research is needed to determine how to raise awareness and put this into practice.
Assuntos
Remoção de Componentes Sanguíneos/efeitos adversos , Transtornos de Deglutição/diagnóstico , Educação em Enfermagem/métodos , Aprendizagem Baseada em Problemas/métodos , Adulto , Conhecimentos, Atitudes e Prática em Saúde , Humanos , Projetos Piloto , Aprendizagem Baseada em Problemas/normas , Estudos Prospectivos , Tamanho da Amostra , Inquéritos e QuestionáriosRESUMO
According to the risk estimates of the Robert-Koch-Institute (RKI) and the Paul Ehrlich-Institute (PEI) an equivalence cannot be assumed to exist between the two different platelet preparations. Differences between single-donor (apheresis) platelet concentrates (ATK) and pooled whole-blood-derived platelet concentrates (PTK) result from donor populations, donation intervals, and preparation techniques. There are no prospective randomized studies with regard to the clinical efficacy, which would unambiguously demonstrate equivalence of the therapeutic efficacy of PTK (buffy coat method) in comparison to ATK. The German Association of Blood Transfusion Services (StKB) points out that, due to the non-equivalence of PTK and ATK, it is incumbent on the transfusion physician to select the platelet concentrate, make the appropriate disclosures, and assume treatment responsibility. Proper compensation for ATK and PTK must be ensured by the health insurance companies, whereby a special indication for the selection of either PTK or ATK is not given. Exceptions are patients with known HLA antibodies in which only selected platelet concentrates may be administered. Otherwise, no indication exists in the selection of the different platelet concentrates (Article is in German).
Assuntos
Remoção de Componentes Sanguíneos/métodos , Plaquetas , Transfusão de Plaquetas/métodos , Remoção de Componentes Sanguíneos/efeitos adversos , Humanos , Segurança do Paciente , Transfusão de Plaquetas/efeitos adversos , Medição de Risco , Fatores de Risco , Resultado do TratamentoRESUMO
Hypertriglyceridemia is associated with a number of severe diseases such as acute pancreatitis and coronary artery disease. In severe hypertriglyceridemia (SHTG, triglycerides > 1,000 mg/dL), rapid lowering of plasma triglycerides (TG) has to be achieved. Treatment regimes include nutritional intervention, the use of antihyperlipidemic drugs, and therapeutic apheresis. Apheretic treatment is indicated in medical emergencies such as hypertriglyceridemic pancreatitis. Reviewing the current literature, plasmapheresis appears to be a safe and useful therapeutic tool in patients suffering from SHTG. Apheretic treatment is able to remove the causative agent for pancreatic inflammation. Data suggests that the use of apheresis should be performed as early as possible in order to achieve best results. The use of plasmapheresis, however, is limited due to the rather high costs and the limited availability of the procedure.
Assuntos
Remoção de Componentes Sanguíneos/métodos , Hipertrigliceridemia/terapia , Triglicerídeos/sangue , Remoção de Componentes Sanguíneos/efeitos adversos , Remoção de Componentes Sanguíneos/economia , Humanos , Hipertrigliceridemia/complicações , Hipertrigliceridemia/fisiopatologia , Hipolipemiantes/uso terapêutico , Pancreatite/etiologia , Pancreatite/terapia , Plasmaferese/economia , Plasmaferese/métodos , Índice de Gravidade de Doença , Fatores de TempoRESUMO
BACKGROUND: Standard treatment of newly diagnosed HFE hemochromatosis patients is phlebotomy. Erythrocytapheresis provides a new therapeutic modality that can remove up to three times more red blood cells per single procedure and could thus have a clinical and economic benefit. STUDY DESIGN AND METHODS: To compare the number of treatment procedures between erythrocytapheresis and phlebotomy needed to reach the serum ferritin (SF) target level of 50 µg/L, a two-treatment-arms, randomized trial was conducted in which 38 newly diagnosed patients homozygous for C282Y were randomly assigned in a 1:1 ratio to undergo either erythrocytapheresis or phlebotomy. A 50% decrease in the number of treatment procedures for erythrocytapheresis compared to phlebotomy was chosen as the relevant difference to detect. RESULTS: Univariate analysis showed a significantly lower mean number of treatment procedures in the erythrocytapheresis group (9 vs. 27; ratio, 0.33; 95% confidence interval [CI], 0.25-0.45; Mann-Whitney p < 0.001). After adjustments for the two important influential factors initial SF level and body weight, the reduction ratio was still significant (0.43; 95% CI, 0.35-0.52; p < 0.001). Cost analysis showed no significant difference in treatment costs between both procedures. The costs resulting from productivity loss were significantly lower for the erythrocytapheresis group. CONCLUSION: Erythrocytapheresis is highly effective treatment to reduce iron overload and from a societal perspective might potentially also be a cost-saving therapy.
Assuntos
Remoção de Componentes Sanguíneos/métodos , Eritrócitos , Hemocromatose/terapia , Flebotomia/métodos , Adulto , Remoção de Componentes Sanguíneos/efeitos adversos , Remoção de Componentes Sanguíneos/economia , Feminino , Custos de Cuidados de Saúde , Hemocromatose/sangue , Hemocromatose/genética , Proteína da Hemocromatose , Antígenos de Histocompatibilidade Classe I/genética , Homozigoto , Humanos , Sobrecarga de Ferro/genética , Sobrecarga de Ferro/terapia , Masculino , Proteínas de Membrana/genética , Pessoa de Meia-Idade , Modelos Cardiovasculares , Flebotomia/efeitos adversos , Flebotomia/economia , Estudos Prospectivos , Qualidade de Vida , Resultado do TratamentoRESUMO
Human plasma for therapeutic use, besides having optimal viral safety, must contain optimal levels of all coagulation factors and protease inhibitors to be clinically effective. Several new technologies for pathogen reduction of plasma (PRT) exist and are entering the stage of clinical testing. The main objective of this overview is to provide an update on the current states of three promising photoactive technologies that target pathogen nucleic acid for pathogen inactivation, applicable to single unit fresh-frozen plasma (FFP) and to highlight the experiences gained with classical pathogen reduction of pooled plasma using solvent-detergent (SD) treatment. It should be emphasized that none of the currently applied methods inactivate all types of pathogens and all have some effect on plasma quality when compared to fresh-frozen plasma. Pooled SD-plasma is the best documented clinical product, followed by methylene blue light treated (MBLT)-plasma. Recently, Psoralen light treated (PLT)-plasma has been introduced (CE-marked product in Europe) while Riboflavin light treated (RLT)-plasma is still under development. In principal, PRT for plasma not only differs in terms of the spectrum and log of pathogen reduction potential, but also in respect to the physicochemical/biological characteristics, and profiles of the adverse reactions, particularly in vulnerable patient groups. Therefore, an additional practical step such as oil extraction followed by chromatography to remove the solvent/detergent, and filtration or the use of some special absorbing matrix is required to reduce the residual photosensitive chemicals, their metabolites and photo adducts. This is required to improve the safety margin of the final product. Moreover, while it may be convenient to think that a combined pathogen reduction technology could improve the spectrum of known pathogens to be inactivated, one needs, in practice, to balance between the degree of pathogen reduction and the loss of some plasma protein activity. From the quality point of view, SD-plasma is a pooled standardized pharmaceutical product with extensive in-process control. However, both differences in production processes and the plasma source can influence final product quality. On the other hand, single unit plasma derived from nucleic acid PRT cannot be monitored by pharmaceutical process control and demonstrates the wide range of concentrations normally observed for plasma proteins. Pooling has the disadvantage that one single plasma unit can contaminate a whole pool, but this can be offset by several advantages that pooling and the SD process offer. Among these are reduction of a possible pathogen load by dilution and by neutralizing antibodies in the plasma pool, dilution and possible neutralization of antibodies and allergens which essentially eliminates transfusion-related acute lung injury (TRALI) and reduces allergic reactions significantly, removal of residual blood cells, cell fragments and bacteria, and removal of the largest von Willebrand-factor (vWF) molecules. On the other hand, some streamlining is required for technologies using single units of plasma, such as the use of plasma from male non-transfused donors to reduce TRALI and to avoid the O blood group in order to meet current specifications for FFP [Seghatchian J. What is happening? Are the current acceptance criteria for therapeutic plasma adequate? Transfus Apheresis Sci 2004; 31:67-79], and to exploit the potential benefit to inactivate residual lymphocytes and prevent transfusion-associated graft versus host disease. The cost effectiveness of pathogen inactivation is very low (> 2 million US dollar/life year saved), if however, non-infectious complications such as TRALI are taken into account; the cost for SDP is reduced to < 50,000 British pound/life year saved for those 48 years. Finally, from the therapeutic standpoint, two important questions still remain to be answered. First, whether the various pathogen reduced plasma products are clinically interchangeable and second, whether the conventional quality requirements of FFP are still adequate for the newer plasma products. These questions can only be answered by a head to head comparison, followed by large-scale clinical trials.
Assuntos
Remoção de Componentes Sanguíneos , Transfusão de Componentes Sanguíneos , Preservação de Sangue , Criopreservação , Desinfecção/métodos , Plasma , Remoção de Componentes Sanguíneos/efeitos adversos , Remoção de Componentes Sanguíneos/economia , Remoção de Componentes Sanguíneos/métodos , Transfusão de Componentes Sanguíneos/efeitos adversos , Transfusão de Componentes Sanguíneos/economia , Preservação de Sangue/efeitos adversos , Preservação de Sangue/economia , Preservação de Sangue/métodos , Criopreservação/economia , Criopreservação/métodos , Desinfecção/economia , Humanos , Controle de QualidadeRESUMO
Familial hypercholesterolemia (FH) not adequately responding to diet and drug therapy represents an indication for extracorporeal lipid-apheresis, which has become an highly effective and approved therapy for those patients in several countries. Based on different methodology, five treatment options of lipid-apheresis exist and are in widespread practical use covered by regular reimbursement in Germany. All methods are safe and demonstrate equivalent efficacy of reducing LDL cholesterol with respect to the single apheresis session as well as during long-term treatment. Therefore German reimbursement guidelines leave the choice of the method to the discretion of the apheresis center. Related to properties of the used technology all methods exhibit characteristic patterns of additional plasma protein elimination, which do not impair, but in part may increase the therapeutic benefit of lipid-apheresis. Fibrinogen reduction has to be mentioned as an example. The Lipidfiltration system is based on plasmafiltration previously referred to as membrane differential filtration (MDF), synonymous with double filtration plasmapheresis (DFPP). The new term Lipidfiltration was the result of technological progress in the manufacturing process of the plasmafilter resulting in enhanced sieving characteristics and capacity. The Lipidfiltration system is completed by a specifically designed therapy machine with optimised performance characteristics.
Assuntos
Remoção de Componentes Sanguíneos/métodos , Hiperlipoproteinemia Tipo II/terapia , Lipoproteínas LDL/sangue , Remoção de Componentes Sanguíneos/efeitos adversos , Remoção de Componentes Sanguíneos/economia , LDL-Colesterol/sangue , Humanos , Hiperlipoproteinemia Tipo II/sangue , Hiperlipoproteinemia Tipo II/diagnóstico , Plasmaferese/métodos , Sensibilidade e Especificidade , Índice de Gravidade de Doença , Resultado do TratamentoRESUMO
Immunoadsorption treatment is a non-drug therapy for rheumatoid arthritis. The treatment is based on filtering the patient's plasma through a column containing staphylococcal protein A. The treatment is effective in alleviating the symptoms of severe rheumatoid arthritis in some patients. Data on long-term outcomes are not available. The mechanism of action of this treatment is unclear. Most adverse effects are associated with the apheresis procedure. The cost per 12 week course of treatment is likely to be more than C $20,000. The cost-effectiveness of the technology is not yet established.
Assuntos
Artrite Reumatoide/terapia , Remoção de Componentes Sanguíneos/economia , Técnicas de Imunoadsorção , Remoção de Componentes Sanguíneos/efeitos adversos , Canadá , Análise Custo-Benefício , Custos e Análise de Custo , Aprovação de Equipamentos , Europa (Continente) , Medicina Baseada em Evidências , Humanos , Avaliação de Resultados em Cuidados de Saúde , Proteína Estafilocócica A/uso terapêuticoAssuntos
Bancos de Sangue/tendências , Remoção de Componentes Sanguíneos/efeitos adversos , Transfusão de Sangue/normas , Qualidade de Produtos para o Consumidor/normas , Leucócitos/imunologia , Bancos de Sangue/economia , Bancos de Sangue/normas , Remoção de Componentes Sanguíneos/economia , Remoção de Componentes Sanguíneos/métodos , Análise Custo-Benefício , Humanos , Leucócitos/virologia , Países BaixosAssuntos
Remoção de Componentes Sanguíneos/normas , Transfusão de Componentes Sanguíneos/normas , Leucócitos/imunologia , Adjuvantes Imunológicos , Remoção de Componentes Sanguíneos/efeitos adversos , Remoção de Componentes Sanguíneos/economia , Transfusão de Componentes Sanguíneos/efeitos adversos , Transfusão de Componentes Sanguíneos/economia , Custos e Análise de Custo , Síndrome de Creutzfeldt-Jakob/prevenção & controle , Europa (Continente) , Humanos , Sistema Imunitário/fisiopatologia , Política Pública , Estados UnidosAssuntos
Remoção de Componentes Sanguíneos , Hiperlipoproteinemia Tipo II/terapia , Lipídeos/sangue , Avaliação da Tecnologia Biomédica , Remoção de Componentes Sanguíneos/efeitos adversos , Planos de Seguro Blue Cross Blue Shield , Ensaios Clínicos como Assunto , Aprovação de Equipamentos , Cardiopatias/etiologia , Humanos , Hiperlipoproteinemia Tipo II/complicações , Hiperlipoproteinemia Tipo II/genética , Resultado do Tratamento , Estados Unidos , United States Food and Drug AdministrationRESUMO
A "snapshot" survey of physician coverage for evaluation and supervision of therapeutic apheresis procedures shows significant variation in current clinical practice between 39 blood center-and 41 non-blood center-based programs. Whereas 56% of blood center-based programs usually require physician's "in person" evaluation of the patient, 86% of non-blood center programs do (P < .005). Similarly, non-blood center-based programs were more likely to have physicians on the premises to supervise first and subsequent procedures and to bill separately for medical coverage. These differences were unrelated to location of the procedure (in hospital, blood bank, outpatient department, or other), the size of the program, or any information provided on adverse reactions.